| Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY‐3+) V Leroy, P Angus, JP Bronowicki, GJ Dore, C Hezode, S Pianko, S Pol, ... Hepatology 63 (5), 1430-1441, 2016 | 340 | 2016 |
| Hepatocyte growth factor/scatter factor‐induced intracellular signalling KA Stuart, SM Riordan, S Lidder, L Crostella, R Williams, GG Skouteris International journal of experimental pathology 81 (1), 17-30, 2000 | 177 | 2000 |
| Global multi-stakeholder endorsement of the MAFLD definition N Méndez-Sánchez, E Bugianesi, RG Gish, F Lammert, H Tilg, ... The lancet Gastroenterology & hepatology 7 (5), 388-390, 2022 | 164 | 2022 |
| Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis AJ Muir, F Poordad, J Lalezari, G Everson, GJ Dore, R Herring, A Sheikh, ... Jama 313 (17), 1736-1744, 2015 | 158 | 2015 |
| The C282Y mutation in the haemochromatosis gene (HFE) and hepatitis C virus infection are independent cofactors for porphyria cutanea tarda in Australian patients KA Stuart, F Busfield, EC Jazwinska, P Gibson, LA Butterworth, ... Journal of Hepatology 28 (3), 404-409, 1998 | 149 | 1998 |
| The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial LA Adams, DH Crawford, K Stuart, MJ House, TGS Pierre, M Webb, ... Hepatology 61 (5), 1555-1564, 2015 | 130 | 2015 |
| Underappreciation of non‐alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis PJ Patel, X Banh, LU Horsfall, KL Hayward, F Hossain, T Johnson, ... Internal medicine journal 48 (2), 144-151, 2018 | 101 | 2018 |
| Serum ferritin concentration predicts mortality in patients awaiting liver transplantation NM Walker, KA Stuart, RJ Ryan, S Desai, S Saab, JA Nicol, LM Fletcher, ... Hepatology 51 (5), 1683-1691, 2010 | 95 | 2010 |
| Patient and graft survival after liver transplantation for hereditary hemochromatosis: implications for pathogenesis DHG Crawford, LM Fletcher, SG Hubscher, KA Stuart, E Gane, PW Angus, ... Hepatology 39 (6), 1655-1662, 2004 | 93 | 2004 |
| Duodenal expression of iron transport molecules in untreated haemochromatosis subjects KA Stuart, GJ Anderson, DM Frazer, LW Powell, M McCullen, LM Fletcher, ... Gut 52 (7), 953-959, 2003 | 82 | 2003 |
| Effects of antibiotic therapy in primary sclerosing cholangitis with and without inflammatory bowel disease: a systematic review and meta-analysis A Shah, D Crawford, D Burger, N Martin, M Walker, NJ Talley, C Tallis, ... Seminars in Liver Disease 39 (04), 432-441, 2019 | 66 | 2019 |
| A pragmatic approach identifies a high rate of nonalcoholic fatty liver disease with advanced fibrosis in diabetes clinics and at‐risk populations in primary care PJ Patel, F Hossain, LU Horsfall, X Banh, KL Hayward, S Williams, ... Hepatology communications 2 (8), 897-909, 2018 | 65 | 2018 |
| Increased hepatic iron and cirrhosis: no evidence for an adverse effect on patient outcome following liver transplantation KA Stuart, LM Fletcher, AD Clouston, SV Lynch, DM Purdie, P Kerlin, ... Hepatology 32 (6), 1200-1207, 2000 | 60 | 2000 |
| Multimorbidity and polypharmacy in diabetic patients with NAFLD: Implications for disease severity and management PJ Patel, KL Hayward, R Rudra, LU Horsfall, F Hossain, S Williams, ... Medicine 96 (26), e6761, 2017 | 59 | 2017 |
| Quantitative analysis of the expression of ACAT 1 genes in human tissues by real-time PCR2 JL Smith, K Rangaraj, R Simpson, DJ Maclean, LK Nathanson, KA Stuart, ... Journal of lipid research 45 (4), 686-696, 2004 | 54 | 2004 |
| The social media index as an indicator of quality for emergency medicine blogs: a METRIQ study B Thoma, TM Chan, P Kapur, D Sifford, M Siemens, M Paddock, F Ankel, ... Annals of emergency medicine 72 (6), 696-702, 2018 | 51 | 2018 |
| Hepatic iron concentration correlates with insulin sensitivity in nonalcoholic fatty liver disease L Britton, K Bridle, J Reiling, N Santrampurwala, L Wockner, H Ching, ... Hepatology communications 2 (6), 644-653, 2018 | 50 | 2018 |
| Medication‐related problems in outpatients with decompensated cirrhosis: opportunities for harm prevention KL Hayward, PJ Patel, PC Valery, LU Horsfall, CY Li, PL Wright, CJ Tallis, ... Hepatology communications 3 (5), 620-631, 2019 | 49 | 2019 |
| Efficacy and safety of mycophenolate mofetil in patients with autoimmune hepatitis and suboptimal outcomes after standard therapy SK Roberts, R Lim, S Strasser, A Nicoll, A Gazzola, J Mitchell, W Siow, ... Clinical Gastroenterology and Hepatology 16 (2), 268-277, 2018 | 49 | 2018 |
| Increasing hospitalization rates for cirrhosis: overrepresentation of disadvantaged Australians EE Powell, R Skoien, T Rahman, PJ Clark, J O'Beirne, G Hartel, KA Stuart, ... EClinicalMedicine 11, 44-53, 2019 | 46 | 2019 |
